Men's Health
February 1999
in “
Drugs in R & D
”
TLDR The document concludes that various drugs for men's health issues are in development, with treatments for sexual dysfunction and prostate conditions being the most advanced.
The 1999 document provides a comprehensive review of drugs in development for men's health issues, including alopecia, with 8 agents in clinical development but none beyond phase II. It highlights the successful launch of sildenafil for sexual dysfunction and the development of 13 other drugs in this category. Testosterone enanthate was used for male contraception but required weekly injections, and 7 other agents were being developed. Osteoporosis in men was addressed with droloxifene in phase II and alendronate in phase III trials. Follitropin-a was approved in the EU for hypogonadotropic hypogonadism, and testosterone replacement therapies like Unimed's testosterone gel were in preregistration in the US. Prostate cancer treatments included endocrine therapy and cytotoxic agents, with several in phase III. For benign prostatic hyperplasia, 13 drugs were in development, including bunazosin in preregistration and dutasteride in phase III. The document also provided a profile table with details on drugs by indication and development phase.
